Molecular classification of hepatocellular adenoma in clinical practice.

[1]  S. Imbeaud,et al.  Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. , 2017, Gastroenterology.

[2]  S. Imbeaud,et al.  Genotype‐phenotype correlation of CTNNB1 mutations reveals different ß‐catenin activity associated with liver tumor progression , 2016, Hepatology.

[3]  F. Pruvot,et al.  Liver transplantation for adenomatosis: European experience , 2016, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[4]  H. Reeves.  EASL Clinical Practice Guidelines on the management of benign liver tumours. , 2016, Journal of hepatology.

[5]  A. Luciani,et al.  Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis , 2016, Modern Pathology.

[6]  C. Sempoux,et al.  Hepatocellular nodules expressing markers of hepatocellular adenomas in Budd-Chiari syndrome and other rare hepatic vascular disorders. , 2015, Journal of hepatology.

[7]  A. Luciani,et al.  Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine‐enhanced hepatobiliary phase MRI , 2015, Journal of magnetic resonance imaging : JMRI.

[8]  J. Belghiti,et al.  Will weight loss become a future treatment of hepatocellular adenoma in obese patients? , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[9]  J. Zucman‐Rossi,et al.  Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. , 2015, Gastroenterology.

[10]  A. Ba-Ssalamah,et al.  Morphologic and Molecular Features of Hepatocellular Adenoma with Gadoxetic Acid-enhanced MR Imaging. , 2015, Radiology.

[11]  François Cauchy,et al.  Diagnosis and management of solid benign liver lesions , 2014, Nature Reviews Gastroenterology &Hepatology.

[12]  Jorge M. Fuentes-Orrego,et al.  Inflammatory hepatocellular adenomas can mimic focal nodular hyperplasia on gadoxetic acid-enhanced MRI. , 2014, AJR. American journal of roentgenology.

[13]  A. Luciani,et al.  Open and laparoscopic resection of hepatocellular adenoma: trends over 23 years at a specialist hepatobiliary unit. , 2014, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[14]  T. V. van Gulik,et al.  Risk factors for bleeding in hepatocellular adenoma , 2014, The British journal of surgery.

[15]  Jessica Zucman-Rossi,et al.  Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. , 2014, Cancer cell.

[16]  J. Zucman‐Rossi,et al.  Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma , 2013, Oncoimmunology.

[17]  Zainab Jagani,et al.  Unraveling the therapeutic potential of the Hedgehog pathway in cancer , 2013, Nature Medicine.

[18]  George A. R. Wiggins,et al.  Primary hepatocellular neoplasms in a MODY3 family with a novel HNF1A germline mutation. , 2013, Journal of hepatology.

[19]  Jessica Zucman-Rossi,et al.  Hepatocellular benign tumors-from molecular classification to personalized clinical care. , 2013, Gastroenterology.

[20]  J. Zucman‐Rossi,et al.  Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. , 2013, Journal of hepatology.

[21]  J. Zucman‐Rossi,et al.  Immunohistochemical Markers on Needle Biopsies Are Helpful for the Diagnosis of Focal Nodular Hyperplasia and Hepatocellular Adenoma Subtypes , 2012, The American journal of surgical pathology.

[22]  Yasunori Sato,et al.  A serum amyloid A-positive hepatocellular neoplasm arising in alcoholic cirrhosis: a previously unrecognized type of inflammatory hepatocellular tumor , 2012, Modern Pathology.

[23]  R. D. de Man,et al.  Systematic review of haemorrhage and rupture of hepatocellular adenomas , 2012, The British journal of surgery.

[24]  Aleksandar Sekulic,et al.  Efficacy and safety of vismodegib in advanced basal-cell carcinoma. , 2012, The New England journal of medicine.

[25]  J. Ijzermans,et al.  Can a decision‐making model be justified in the management of hepatocellular adenoma? , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[26]  J. Tran van Nhieu,et al.  GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. , 2012, Journal of hepatology.

[27]  M. Thomeer,et al.  Hepatocellular adenomas: correlation of MR imaging findings with pathologic subtype classification. , 2011, Radiology.

[28]  J. Zucman‐Rossi,et al.  Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas , 2011, The Journal of experimental medicine.

[29]  J. Ijzermans,et al.  Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice. , 2011, Journal of hepatology.

[30]  M. Ronot,et al.  Hepatocellular adenomas: Accuracy of magnetic resonance imaging and liver biopsy in subtype classification , 2011, Hepatology.

[31]  J. Zucman‐Rossi,et al.  Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers. , 2011, Seminars in liver disease.

[32]  V. Paradis,et al.  Changing trends in malignant transformation of hepatocellular adenoma , 2010, Gut.

[33]  Sandrine Imbeaud,et al.  Loss of hepatocyte nuclear factor 1α function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis , 2010, Hepatology.

[34]  V. Paradis,et al.  A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. , 2009, Gastroenterology.

[35]  J. Zucman‐Rossi,et al.  Hepatocellular adenoma management and phenotypic classification: The Bordeaux experience , 2009, Hepatology.

[36]  B. Cieply,et al.  Unique phenotype of hepatocellular cancers with exon‐3 mutations in beta‐catenin gene , 2009, Hepatology.

[37]  S. Imbeaud,et al.  Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours , 2009, Nature.

[38]  J. Zucman‐Rossi,et al.  Hepatocellular adenomas: Magnetic resonance imaging features as a function of molecular pathological classification , 2008, Hepatology.

[39]  Cristel G. Thomas,et al.  Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry , 2007, Hepatology.

[40]  M. Ronot,et al.  Telangiectatic adenoma: An entity associated with increased body mass index and inflammation , 2007, Hepatology.

[41]  J. Zucman‐Rossi,et al.  Regressive liver adenomatosis following androgenic progestin therapy withdrawal: a case report with a 10-year follow-up and a molecular analysis. , 2007, European journal of endocrinology.

[42]  C. Auffray,et al.  HNF1α Inactivation Promotes Lipogenesis in Human Hepatocellular Adenoma Independently of SREBP-1 and Carbohydrate-response Element-binding Protein (ChREBP) Activation* , 2007, Journal of Biological Chemistry.

[43]  S. Monga,et al.  WNT/β‐catenin signaling in liver health and disease , 2007 .

[44]  J. Zucman‐Rossi,et al.  Inflammatory syndrome with liver adenomatosis: the beneficial effects of surgical management , 2007, Gut.

[45]  S. Monga,et al.  WNT/beta-catenin signaling in liver health and disease. , 2007, Hepatology.

[46]  J. Zucman‐Rossi,et al.  Genotype–phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC , 2006, Hepatology.

[47]  J. Zucman‐Rossi,et al.  Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. , 2005, Gastroenterology.

[48]  V. Paradis,et al.  Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. , 2004, Gastroenterology.

[49]  J. Zucman‐Rossi,et al.  Hepatocyte nuclear factor-1 alpha gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families. , 2004, The Journal of clinical endocrinology and metabolism.

[50]  J. Zucman‐Rossi,et al.  Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation. , 2003, Gastroenterology.

[51]  J. Zucman‐Rossi,et al.  Bi-allelic inactivation of TCF1 in hepatic adenomas , 2002, Nature Genetics.

[52]  P. Bioulac-Sage,et al.  Liver adenomatosis: reappraisal, diagnosis, and surgical management: eight new cases and review of the literature. , 2000, Annals of surgery.

[53]  T. Hansen,et al.  Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young (MODY3) , 1996, Nature.

[54]  A. Rahmouni,et al.  Management of focal nodular hyperplasia and hepatocellular adenoma in young women: A series of 41 patients with clinical, radiological, and pathological correlations , 1995, Hepatology.

[55]  C. Degott,et al.  Liver adenomatosis. An entity distinct from liver adenoma? , 1985, Gastroenterology.

[56]  K. Ishak,et al.  The Association Between Oral Contraception and Hepatocellular Adenoma — A Preliminary Report , 1977, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[57]  B. Henderson,et al.  Liver-cell adenomas associated with use of oral contraceptives. , 1976, The New England journal of medicine.